1차 출처 기록
중대신청 제출
Inhibrx, ozekibart BLA를 2026년 2분기 초 제출 계획
The company stated it will submit a BLA for ozekibart in unresectable or metastatic conventional chondrosarcoma early in the second quarter of 2026. It also guided for PFS data from the colorectal cancer expansion cohort in Q2 2026 and a meeting with FDA to discuss accelerated approval in Ewing sarcoma and fourth-line colorectal cancer in H2 2026.
핵심 사실
- 제출
- 2026년 3월 19일 PM 08:01
- 이벤트
- 신청 제출
- 방향
- 중립
- 출처
- SEC 8-K
- 신뢰도
- 출처 확인
출처 발췌
EX-99.1 2 exhibit99112312025.htm EX-99.1 Document Exhibit 99.1 Inhibrx Reports Fourth Quarter and Fiscal Year 2025 Financial Results San Diego, CA, March 19, 2026 – Inhibrx Biosciences, Inc. (Nasdaq: INBX) (“Inhibrx” or the “Company”) today reported financial results for the fourth quarter and fiscal year 2025. Following the completion of the sale of INBRX-101 (the "101 Transaction") by Inhibrx, Inc. (the “Former Parent”) to Sanofi S.A. (the “Acquirer”) and the Former Parent’s concurrent spin-off of the Inhibrx business in May 2024, the biopharmaceutical company now has two programs in ongoing clinical trials. Upcoming Milestones • ozekibart (INBRX-109) ◦ We expect to submit the Biologics License Application (“BLA”) for ozekibart for the treatment of unresectable or metastatic conventi